Nibix (Imatinib)

Imatinib, the active ingredient in Nibix, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats BCR‑ABL positive malignancies such as chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor. GNH USA supplies Nibix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib targets malignancies driven by BCR‑ABL or related tyrosine‑kinase pathways.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by inhibiting BCR‑ABL positive blasts. - Gastrointestinal stromal tumor (GIST): blocks c‑KIT signaling to limit tumor growth.

Imatinib may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: swelling of the hands, feet or face. - Muscle cramps: especially in the lower limbs. - Fatigue: general tiredness. - Diarrhea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Neutropenia: dangerously low white blood cell count. - Thrombocytopenia: reduced platelet levels leading to bleeding. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: increased pressure in lung arteries.

Before initiating therapy, several safety measures should be observed.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: periodic LFTs to identify hepatotoxicity. - Evaluate cardiac status: watch for signs of heart failure. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Store at room temperature: keep in the original pack, protect from moisture and light.

Imatinib interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): reduce imatinib plasma levels. - Concomitant use with other BCR‑ABL inhibitors: may cause additive toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect absorption; separate dosing by at least 2 hours. - Warfarin: imatinib can potentiate anticoagulant effect; monitor INR. - CYP2C8 inhibitors (e.g., gemfibrozil): modestly raise imatinib concentrations.